2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Sunday, November 5, 2017

11:00AM-12:30PM: Abstract Number: 827

Temporary Methotrexate Discontinuation for 2 Weeks Improves Immunogenicity of Seasonal Influenza Vaccination in Patients with Rheumatoid Arthritis: A Randomized Clinical Trial

Plenary Session I

11:00AM-12:30PM: Abstract Number: 826

TGF-β-Induced Epigenetic Silencing of SOCS3 Facilitates STAT3 Signaling to Promote Fibroblast Activation and Tissue Fibrosis in Systemic Sclerosis

Plenary Session I

11:00AM-12:30PM: Abstract Number: 828

The Impact of the Duration of Bisphosphonate Drug Holidays on Hip Fracture Rates

Plenary Session I

11:00AM-12:30PM: Abstract Number: 829

Unraveling Race and Social Context in Understanding Disparities in Lupus Mortality in the United States

Plenary Session I

2:30PM-4:00PM: Abstract Number: 848

“Suddenly You Are a Person at Risk of Developing Rheumatoid Arthritis!” Different Perspectives of Individuals on Predictive Testing – Results of an International Qualitative Interview Study

ARHP Psychosocial Impact on Rheumatic Disease

2:30PM-4:00PM: Abstract Number: 885

48-Week Complete Remission By Ethnic, Sex and Age Subgroups in Patients with Active Lupus Nephritis Treated with Voclosporin

Systemic Lupus Erythematosus – Clinical Aspects and Treatment I: Novel and Current Therapies

2:30PM-4:00PM: Abstract Number: 882

A New Model of Care for Improving Early Rheumatology Access of Psoriatic Arthritis Patients

Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment I

2:30PM-4:00PM: Abstract Number: 887

A Randomized, Placebo-Controlled, Double-Blind, Ascending-Dose, Safety, and Pharmacokinetics Study of CC-220 in Subjects with Systemic LUPUS Erythematosus

Systemic Lupus Erythematosus – Clinical Aspects and Treatment I: Novel and Current Therapies

2:30PM-4:00PM: Abstract Number: 894

All Oral Interferon-Free Antivirals for Hepatitis C Virus Cryoglobulinemia Vasculitis: A Long Term Follow up Multicenter International Study

Vasculitis I: Clinical Trials and Outcomes

2:30PM-4:00PM: Abstract Number: 853

Anti-TIF-1 Antibody Positivity Is Associated with a Five-Fold Increase in Cancer Risk in the Idiopathic Inflammatory Myopathies

Muscle Biology, Myositis and Myopathies

2:30PM-4:00PM: Abstract Number: 879

Association of Venous Thromboembolism with Spondyloarthopathies Among Hospitalized Patients – Data from National Inpatient Sample

Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment I

2:30PM-4:00PM: Abstract Number: 889

Attainment of Low Disease Activity By Patients with Systemic Lupus Erythematosus Starting with High Disease Activity in a 24-Week, Randomized, Placebo-Controlled, Phase IIb Study of Atacicept (ADDRESS II)

Systemic Lupus Erythematosus – Clinical Aspects and Treatment I: Novel and Current Therapies

2:30PM-4:00PM: Abstract Number: 851

Autoantibodies Predict Long Term Survival in Myositis Associated Interstitial Lung Disease

Muscle Biology, Myositis and Myopathies

2:30PM-4:00PM: Abstract Number: 836

B Cell Receptor Sequencing of Anti-Citrullinated Protein Antibody Expressing B Cells Indicates a Selective Advantage for the Introduction of N-Glycosylation Sites during Somatic Hypermutation

B Cell Biology and Targets in Autoimmune Disease

2:30PM-4:00PM: Abstract Number: 868

Baseline Troponin Levels Are Associated with Mortality in a Cohort of Patients with Inflammatory Polyarthritis: Results from the Norfolk Arthritis Register

Rheumatoid Arthritis – Clinical Aspects I: Cardiac Comorbidities

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].